Ογκολογία Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer Authors: Julien Mazieres et al. 20/01/2020 time to read 2 min read
Ογκολογία Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Authors: Martin Reck et al. 01/03/2019 time to read 2 min read
Ογκολογία Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer Authors: Luis Paz-Ares et al. 22/11/2018 time to read 2 min read
Ογκολογία Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer Authors: Leena Gandhi et al. 31/05/2018 time to read 2 min read
Ογκολογία Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial Authors: Julie R Brahmer et al 01/12/2017 time to read 3 min read
Ογκολογία Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer Authors: Martin Reck et al. 10/11/2016 time to read 2 min read
Καρδιολογία Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial Authors: Gérald Simonneau et al. 01/05/2016 time to read 2 min read
Καρδιολογία Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial Authors: Hossein-Ardeschir Ghofrani et al. 01/05/2016 time to read 2 min read
Καρδιολογία Riociguat for the treatment of chronic thromboembolic pulmonary hypertension Authors: Hossein-Ardeschir Ghofrani et al. 25/07/2013 time to read 3 min read